The Annual General Meeting of Vaccentis AG took place on 20 June 2024 at the offices of Lenz & Staehelin in Zurich. In an informative programme, we were able to highlight the key status of Vaccentis in the development of the tumour vaccine VCC- 001 and outline the key projects that are now necessary in the next 2 to 3 years in order to increase the value of the company accordingly.The introduction of the new capital band presented at the Annual General Meeting in order to drive forward our 2025 and 2026 business plan was approved with 99.2% of the share capital represented and present!
